Literature DB >> 18005808

E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.

Burke A Cunha1, Nardeen Mickail, Lawrence Eisenstein.   

Abstract

Enterococci are part of the normal flora of the gastrointestinal tract. Intra-abdominal and genitourinary enterococcal infections may be complicated by enterococcal bacteremia. Most strains of enterococci fecal flora in antibiotic-naive patients are E. faecalis. Because nearly all E. faecalis strains are sensitive to vancomycin, E. faecalis is synonymous with vancomycin-sensitive enterococci (VSE). E. faecium, which is nearly always vancomycin-resistant, is termed vancomycin-resistant enterococci (VRE). High-grade continuous enterococcal bacteremias may result in endocarditis. Persistent VSE and VRE bacteremias may be related to device-associated infections; intra-abdominal, pelvic, and/or renal abscesses; or enterococcal endocarditis. If these causes of persistent enterococcal bacteremia are eliminated, microbiologic and antimicrobial therapy-related causes for persistent bacteremia should be considered. We present a case of a male with a E. faecalis (VSE) bacteremia unresponsive to parenteral vancomycin therapy but sensitive to vancomycin in vitro (minimum inhibitory concentration [MIC] = 1 microg/mL). The patient was treated with high-dose daptomycin (12 mg/kg intravenously [IV] q 24 hours) empirically pending susceptibility testing. High-dose daptomycin therapy cleared the patient's E. faecalis bacteremia. Subsequently, it was determined that the strain of E. faecalis was "tolerant" of vancomycin (MIC = 1 microg/mL, MBC = >64 microg/mL). We believe this is the first case of enterococcal (VSE) bacteremia unresponsive to vancomycin tolerant strain of E. faecalis that responded to high-dose daptomycin (12 mg/kg IV q 24 hours) therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005808     DOI: 10.1016/j.hrtlng.2007.02.012

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  9 in total

1.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

2.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.

Authors:  Ravina Kullar; Anthony M Casapao; Susan L Davis; Donald P Levine; Jing J Zhao; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2013-08-08       Impact factor: 5.790

4.  Molecular detection of bacterial contamination in plasma using magnetic-based enrichment.

Authors:  Jinyeop Lee; Abdurhaman Teyib Abafogi; Sujin Oh; Ho Eun Chang; Wu Tepeng; Daekyu Lee; Sungsu Park; Kyoung Un Park; Yun Ji Hong
Journal:  Sci Rep       Date:  2022-06-01       Impact factor: 4.996

Review 5.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

6.  High-Level Antibiotic Tolerance of a Clinically Isolated Enterococcus faecalis Strain.

Authors:  Huan Gu; Sweta Roy; Xiaohui Zheng; Tian Gao; Huilin Ma; Zafer Soultan; Christopher Fortner; Shikha Nangia; Dacheng Ren
Journal:  Appl Environ Microbiol       Date:  2020-12-17       Impact factor: 4.792

7.  β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.

Authors:  Shrenik Mehta; Christopher Singh; Konrad B Plata; Palas K Chanda; Arundhati Paul; Sarah Riosa; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

8.  Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

Authors:  Theodoros Kelesidis; Romney Humphries; Daniel Z Uslan; David A Pegues
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 20.999

9.  Daptomycin for the treatment of major gram-positive infections after cardiac surgery.

Authors:  A Kornberger; B Luchting; F Kur; M Weis; F Weis; U A Stock; A Beiras-Fernandez
Journal:  J Cardiothorac Surg       Date:  2016-08-04       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.